Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Catheter Cardiovasc Interv. 2019 Oct 1;94(4):555-561. doi: 10.1002/ccd.28448. Epub 2019 Aug 20.
Determine the outcomes of polytetrafluoroethylene (PTFE) covered stents for coronary artery perforation (CAP) and coronary artery aneurysm (CAA).
PTFE covered stents have been used for treatment of potentially life-threatening CAP and CAA. The short and long-term outcomes of the PTFE covered stent for CAP and CAA have not been well studied.
We performed a retrospective study of PTFE covered stents that were placed in the patients from 2003 to 2017. Short term outcomes included in-hospital mortality, pericardial effusion, cardiac tamponade, and length of stay. Long-term outcomes included target lesion revascularization (TLR), in-stent restenosis (ISR), and long-term mortality.
Fifty-three PTFE covered stents were placed in 32 patients of which there were 24 patients with a CAP with a mean age of 75 ± 8 years. Two patients died in-hospital, with no additional deaths at 30 days. The rate of ISR was 25%, with estimated rates of TLR of 2.6% (3 years) and 17.8% (5 years). The median survival was 55.6 months, with survival at 10 years estimated to be 30.9%. Eight patients received a PTFE covered stent for CAA with a mean age of 59 ± 15 years with no in-hospital or 30-day mortality. Median follow-up of 49 months showed no evidence of TLR. The all-cause mortality was 12% at 1 year and 38% at 3 years.
PTFE covered stents is an effective option in patients with CAP and CAA. The long-term outcomes may be related to the pathology of the disease rather than the stent itself.
确定聚四氟乙烯(PTFE)覆膜支架治疗冠状动脉穿孔(CAP)和冠状动脉瘤(CAA)的结果。
PTFE 覆膜支架已用于治疗潜在危及生命的 CAP 和 CAA。PTFE 覆膜支架治疗 CAP 和 CAA 的短期和长期结果尚未得到很好的研究。
我们对 2003 年至 2017 年期间接受 PTFE 覆膜支架治疗的患者进行了回顾性研究。短期结果包括住院死亡率、心包积液、心脏压塞和住院时间。长期结果包括靶病变血运重建(TLR)、支架内再狭窄(ISR)和长期死亡率。
32 例患者共植入 53 枚 PTFE 覆膜支架,其中 24 例 CAP,平均年龄 75±8 岁。2 例患者住院期间死亡,30 天内无其他死亡。ISR 发生率为 25%,估计 TLR 发生率为 2.6%(3 年)和 17.8%(5 年)。中位生存期为 55.6 个月,10 年生存率估计为 30.9%。8 例 CAA 患者植入 PTFE 覆膜支架,平均年龄 59±15 岁,住院期间及 30 天内无死亡。中位随访 49 个月,无 TLR 证据。1 年时全因死亡率为 12%,3 年时为 38%。
PTFE 覆膜支架是 CAP 和 CAA 患者的有效治疗选择。长期结果可能与疾病的病理而非支架本身有关。